Search - tctmd.com

Displaying 81 - 100 of 102

Sort: Relevancy | Date

News Conference News ACC 2018

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

Yael L. Maxwell

March 19, 2018

News Conference News ACC 2018

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

Caitlin E. Cox

March 11, 2018

News Daily News

The Biggest News of 2017: TCTMD’s Top 10

Shelley Wood

January 01, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Todd Neale

October 30, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2017

Shelley Wood

September 30, 2017

News Daily News

New Performance and Quality Metrics for STEMI and NSTEMI Care

Michael O'Riordan

September 21, 2017

News Opinion Editor's Corner ESC 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

Shelley Wood

September 08, 2017

News Conference News ESC 2017

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

Shelley Wood

September 01, 2017

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Leah Lawrence

July 24, 2017

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Shelley Wood

May 12, 2017

News Daily News

Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value

Todd Neale

May 04, 2017

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

Presentation

Economic Analysis of Ticagrelor TherapyFrom a US Perspective

Presenter: Patricia A. Cowper

February 02, 2015

News Daily News

Long-term Ticagrelor Therapy Cost-Effective in US Patients

L.A. McKeown

February 02, 2015

Presentation TCT 2014

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

Presenter: Dirk Sibbing

September 14, 2014

News Daily News

PCI疗效不受HIV状态的影响

Yael L. Maxwell

July 07, 2014

Advertisement

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

The Biggest News of 2017: TCTMD’s Top 10

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

TCTMD’s Top 10 Most Popular Stories for September 2017

New Performance and Quality Metrics for STEMI and NSTEMI Care

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

ESC Updates Guidelines for Treating STEMI Patients

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

Economic Analysis of Ticagrelor TherapyFrom a US Perspective

Long-term Ticagrelor Therapy Cost-Effective in US Patients

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

PCI疗效不受HIV状态的影响

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content